# ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma

> **NCT06588660** · PHASE1 · TERMINATED · sponsor: **University of Washington** · enrollment: 1 (actual)

## Conditions studied

- Recurrent Multiple Myeloma
- Refractory Multiple Myeloma

## Interventions

- **BIOLOGICAL:** Vevoctadekin
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Bone Marrow Biopsy
- **OTHER:** Medical Chart Review
- **DRUG:** Teclistamab
- **PROCEDURE:** Biospecimen Collection

## Key facts

- **NCT ID:** NCT06588660
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-12-18
- **Primary completion:** 2025-02-14
- **Final completion:** 2025-02-14
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Study terminated due to end of funding.
- **Last updated:** 2025-07-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06588660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06588660, "ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT06588660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*